Page last updated: 2024-11-07

cholestane-3,5,6-triol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cholestane-3,5,6-triol: structure; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID537036
SCHEMBL ID14490136
MeSH IDM0040611

Synonyms (13)

Synonym
LS-15222
cholestane-3,5,6-triol
L024117
FT-0675560
SCHEMBL14490136
cholestan-3beta,5alpha,6beta-triol
YMMFNKXZULYSOQ-UHFFFAOYSA-N
17-(1,5-dimethylhexyl)-10,13-dimethylhexadecahydrocyclopenta[a]phenanthrene-3,5,6-triol
cholestane-3,5,6-triol #
3-beta-5-alpha-6-beta-trihydroxycholestan
35089-25-9
3??5??6?-trihydroxycholestane
cholestane-3,5,6-triol, (3b,5a,6a)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The order of cytotoxic potency of these cholesterol oxides is: cholestane triol greater than cholesterol-beta-epoxide greater than cholesterol-alpha-epoxide, with LD50 concentrations ranging from 23 to greater than 150 microM in confluent cells."( Uptake, metabolism, and cytotoxicity of isomeric cholesterol-5,6-epoxides in rabbit aortic endothelial cells.
Berliner, J; Peterson, H; Sevanian, A, 1991
)
0.28
"Cell necrosis and reactive cellular processes in and near the atherosclerotic core region might result from short-range interactions with toxic lipids."( Focal toxicity of oxysterols in vascular smooth muscle cell culture. A model of the atherosclerotic core region.
Black, BL; Guyton, JR; Seidel, CL, 1990
)
0.28
"The protective effect of ebselen, with documented glutathione peroxidase-like activity and antioxidative and anti-inflammatory properties, on the cytotoxicity induced by oxysterol was investigated in ECV-304 cells with cholestane-3beta, 5alpha, 6beta-triol (3-triol), one of the most toxic oxysterols."( Protective effect of ebselen on cytotoxicity induced by cholestane-3 beta, 5 alpha, 6 beta-triol in ECV-304 cells.
Huang, K; Wu, Q, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (83)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (20.48)18.7374
1990's29 (34.94)18.2507
2000's17 (20.48)29.6817
2010's18 (21.69)24.3611
2020's2 (2.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (1.20%)0.25%
Other81 (97.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]